OBJECTIVE: To evaluate cognitive outcome in adult survivors of bacterial meningitis. METHODS: Data from three prospective multicentre studies were pooled and reanalysed, involving 155 adults surviving bacterial meningitis (79 after pneumococcal and 76 after meningococcal meningitis) and 72 healthy controls. RESULTS: Cognitive impairment was found in 32% of patients and this proportion was similar for survivors of pneumococcal and meningococcal meningitis. Survivors of pneumococcal meningitis performed worse on memory tasks (p<0.001) and tended to be cognitively slower than survivors of meningococcal meningitis (p = 0.08). We found a diffuse pattern of cognitive impairment in which cognitive speed played the most important role. Cognitive performance was not related to time since meningitis; however, there was a positive association between time since meningitis and self-reported physical impairment (p<0.01). The frequency of cognitive impairment and the numbers of abnormal test results for patients with and without adjunctive dexamethasone were similar. CONCLUSIONS: Adult survivors of bacterial meningitis are at risk of cognitive impairment, which consists mainly of cognitive slowness. The loss of cognitive speed is stable over time after bacterial meningitis; however, there is a significant improvement in subjective physical impairment in the years after bacterial meningitis. The use of dexamethasone was not associated with cognitive impairment.
OBJECTIVE: To evaluate cognitive outcome in adult survivors of bacterial meningitis. METHODS: Data from three prospective multicentre studies were pooled and reanalysed, involving 155 adults surviving bacterial meningitis (79 after pneumococcal and 76 after meningococcal meningitis) and 72 healthy controls. RESULTS:Cognitive impairment was found in 32% of patients and this proportion was similar for survivors of pneumococcal and meningococcal meningitis. Survivors of pneumococcal meningitis performed worse on memory tasks (p<0.001) and tended to be cognitively slower than survivors of meningococcal meningitis (p = 0.08). We found a diffuse pattern of cognitive impairment in which cognitive speed played the most important role. Cognitive performance was not related to time since meningitis; however, there was a positive association between time since meningitis and self-reported physical impairment (p<0.01). The frequency of cognitive impairment and the numbers of abnormal test results for patients with and without adjunctive dexamethasone were similar. CONCLUSIONS: Adult survivors of bacterial meningitis are at risk of cognitive impairment, which consists mainly of cognitive slowness. The loss of cognitive speed is stable over time after bacterial meningitis; however, there is a significant improvement in subjective physical impairment in the years after bacterial meningitis. The use of dexamethasone was not associated with cognitive impairment.
Authors: Martijn Weisfelt; Diederik van de Beek; Lodewijk Spanjaard; Johannes B Reitsma; Jan de Gans Journal: Lancet Neurol Date: 2006-02 Impact factor: 44.182
Authors: Diederik van de Beek; Jan de Gans; Lodewijk Spanjaard; Martijn Weisfelt; Johannes B Reitsma; Marinus Vermeulen Journal: N Engl J Med Date: 2004-10-28 Impact factor: 91.245
Authors: Martijn Weisfelt; Martine Hoogman; Diederik van de Beek; Jan de Gans; Wouter A Dreschler; Ben A Schmand Journal: Ann Neurol Date: 2006-10 Impact factor: 10.422
Authors: Diederik van de Beek; Ben Schmand; Jan de Gans; Martijn Weisfelt; Heleen Vaessen; Jacob Dankert; Marinus Vermeulen Journal: J Infect Dis Date: 2002-09-13 Impact factor: 5.226
Authors: Tatiana Barichello; Ana Lucia B Santos; Geovana D Savi; Jaqueline S Generoso; Paola Otaran; Cleonice M Michelon; Amanda V Steckert; Francielle Mina; Clarissa M Comim; Felipe Dal-Pizzol; João Quevedo Journal: Metab Brain Dis Date: 2012-05-17 Impact factor: 3.584
Authors: Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek Journal: Clin Microbiol Rev Date: 2011-07 Impact factor: 26.132
Authors: Madelijn Geldhoff; Barry B Mook-Kanamori; Matthijs C Brouwer; Mercedes Valls Seron; Frank Baas; Arie van der Ende; Diederik van de Beek Journal: Immunogenetics Date: 2012-09-30 Impact factor: 2.846